AtriCure Enters Into Definitive Agreement to Acquire nContact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Canaccord Genuity Cuts Price Target on AtriCure (ATRC) on Current Weakness
October 6, 2015 8:55 AM EDTCanaccord Genuity maintained a Buy rating on AtriCure Inc. (NASDAQ: ATRC), and cut the price target to $28.00 (from $31.00), on current weakness. Analyst Jason Mills recommend investors add to positions in ATRC on weakness associated with the nContact deal.
Mills Commented, "We recommend investors add to positions in ATRC on weakness associated with the nContact deal. We believe this business combination will 1) strengthen AtriCures presence in the AF market; 2) expand its... More
AtriCure (ATRC) to Acquire nContact in Cash, Stock Deal
October 5, 2015 6:41 AM EDTAtriCure (NASDAQ: ATRC) announced that it has entered into a definitive merger agreement under which AtriCure has agreed to acquire nContact, Inc., a privately held developer of innovative cardiac ablation solutions.
The transaction consideration consists of an upfront payment of approximately 3.7 million shares of AtriCure common stock, valued at $24.60 per share, and approximately $8 million in cash, subject to closing adjustments. The transaction also includes up to $50 million in additional contingent consideration based on completion of enrollment of the CONVERGE IDE trial and PMA approval. Additionally, nContact shareholders are entitled to additional sales-based... More
